GSK intends to manufacture, fill and finish adjuvant for Covid-19 vaccines at sites in the UK, US, Canada and Europe. Credit: GSK.
GlaxoSmithKline (GSK) is set to produce one billion doses of its pandemic vaccine adjuvant system next year to support adjuvanted Covid-19 vaccine candidates development.
The news comes after the company performed global manufacturing review and decided to invest for expanded manufacturing capacity.
In the last flu pandemic, GSK pandemic adjuvant decreased the amount of vaccine protein needed per dose, facilitating the production of more vaccine doses.